control group:Carrelizumab 200mg, paclitaxel 135mg/m2, cisplatin 75mg/m2 or carboplatin AUC5 were administered intravenously once every 3 weeks
Sponsors
Department of Oncology, the Eighth People's Hospital of Jinan, Jinan Eighth People's Hospital
Conditions
Lung cancer
Early Phase 1
Efficacy and safety of Sintilimab combined with pegylated recombinant human granulocyte colony stimulating factor in the treatment of metastatic NSCLC
Active, not recruitingChiCTR2200063209
Start: 2022-09-01Updated: 2023-04-17
Efficacy and safety of PEG-rhG-CSF Combined with Camrelizumab and Chemotherapy in the Treatment of advanced squamous non-small cell lung cancer
Active, not recruitingChiCTR2400094635
Start: 2022-06-01Updated: 2025-01-06